ClinicalTrials.gg
Enrolling by invitationNCT06610968Updated Nov 16, 2026

Acute Vitamin D Supplementation on Testosterone in Females

An interventional study of Vitamin D (Cholecalciferol ) and Placebo Group in Female Hormone Profile, sponsored by University of Southern California. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Southern California · Not applicable, Interventional, and Health services research

How we know

Updated Nov 16, 2026Now Enrolling by invitationPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Participation will take place over two visits to the Clinical Exercise Research Center (CERC) at the University of Southern California Health Sciences Campus.

On the first visit, height, weight, and body composition by bioelectrical impedance are recorded. Questionnaires and withdrawal of a sample of blood (1 tablespoon) are also completed. The intervention begins the day following the first visit. The intervention protocol consists of three weeks of consuming either a placebo capsule or a 5000 IU Vitamin D capsule daily and completing a daily survey.

The second visit to CERC immediately follows the 3-weeks intervention. In this visit, the same blood sampling protocol will be completed. The assignment of the intervention will be randomized (i.e., rolling a die), and participants are blinded to group assignment.

Read the detailed description

High-dose Vitamin D supplementation significantly increases testosterone in men, but research about Vitamin D's effect on testosterone in young, healthy females is limited [1]. However, testosterone is a critical hormone for many physiologic functions in females including maintenance of reproductive health, cognitive function, body composition, mental health, bone density, muscle strength, and much more. Thus, this study aims to investigate the effect of Vitamin D supplementation on testosterone and gonadotropin concentrations in premenopausal, healthy females. The study investigators hypothesize that Vitamin D supplementation will result in a significant increase in circulating Vitamin D [25(OH)D], testosterone, and sex hormone modulators (i.e., gonadotropins and SHBG) concentrations in pre-menopausal females and that the magnitude of testosterone increase will be inversely related to fat mass and BMI. 20 young, healthy females will be randomized to either a treatment or placebo group for a three-week intervention, where the control group will take 5000 IU of Vitamin D orally, daily and the placebo group will take a placebo capsule orally, daily. Circulating Vitamin D, testosterone, gonadotropin, and SHBG concentrations will be assessed via serum pre- and post-intervention. Two-tailed unpaired t-test will be conducted to assess the relative change in total testosterone and free testosterone levels between the groups. Additionally, correlation analyses will be performed for correlations between body composition metrics and 25(OH)D, testosterone, and sex hormone modulator concentrations.

02

Conditions studied

  • Female Hormone Profile
03

In context

Lead sponsor

University of Southern California is the lead sponsor of 793 studies on the registry; 138 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 32 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Assigned female at birth
  • 18 to 35 years of age
  • No chronic diseases affecting the uptake of Vitamin D or causing Vitamin D sensitivity (e.g., sarcoidosis, tuberculosis, Wegener's granulomatosis, other forms of vasculitis, inflammatory bowel diseases, etc.) [21]
  • Completion and signature of the document
  • Non-pregnant or trying to become pregnant
  • No supplementation with Vitamin D within three months of enrollment
  • No documented gynecological disease (e.g., PCOS, endometriosis, etc.)
  • Weight greater than or equal to 110 lbs

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Supplementation with Vitamin D within three months of enrollment
  • Taking exogenous hormones
  • Documented gynecological disease (e.g., PCOS, endometriosis, etc.)
  • Suffering from chronic diseases affecting the uptake of Vitamin D or causing Vitamin D sensitivity (e.g., sarcoidosis, tuberculosis, Wegener's granulomatosis, other forms of vasculitis, inflammatory bowel diseases, etc.) [21]
  • Weight less than 110 lbs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Vitamin D Group

    The treatment intervention will consist of three weeks of one 5000 IU cholecalciferol capsule (Pure Encapsulations, LLC) daily, with breakfast.

    Dietary Supplement: Vitamin D (Cholecalciferol )

  • Placebo comparator
    Placebo Group

    The control group will also take a daily, with breakfast, placebo capsule (Zeebo) for the three-week intervention.

    Dietary Supplement: Placebo Group

Interventions

  • Dietary supplementVitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5000 IU Vitamin D (as cholecalciferol) capsules (Vitamin D3 125 mcg \[5,000 IU\], Pure Encapsulation, LLC) daily

    Also known as: 5000 IU Vitamin D daily

  • Dietary supplementPlacebo Group

    One placebo capsule (Zeebo Imagine, Zeebo) daily.

    Also known as: Placebo (Zeebo) pill daily

06

What researchers measure

Primary outcomes

  1. Hormonal Effects of Vitamin D in Young, Healthy Women

    The primary objective is to evaluate the effect of acute Vitamin D supplementation on systemic Vitamin D, testosterone, and sex hormone modulators in pre-menopausal, healthy females. Circulating testosterone (total testosterone and free testosterone) concentrations (ng/dL) will be assessed via serum pre- and post-Vitamin D intervention.

    Time frame: 3 weeks

  2. Hormonal Effects of Vitamin D in Young, Healthy Women

    The primary objective is to evaluate the effect of acute Vitamin D supplementation on systemic Vitamin D, testosterone, and sex hormone modulators in pre-menopausal, healthy females. Circulating Vitamin D \[25(OH)D\] concentrations (ng/dL) will be assessed via serum pre- and post-Vitamin D intervention.

    Time frame: 3 weeks

  3. Hormonal Effects of Vitamin D in Young, Healthy Women

    The primary objective is to evaluate the effect of acute Vitamin D supplementation on systemic Vitamin D, testosterone, and sex hormone modulators in pre-menopausal, healthy females. Circulating gonadotropins (LH and FSH) concentrations (IU/L) will be assessed via serum pre- and post-Vitamin D intervention.

    Time frame: 3 weeks

  4. Hormonal Effects of Vitamin D in Young, Healthy Women

    The primary objective is to evaluate the effect of acute Vitamin D supplementation on systemic Vitamin D, testosterone, and sex hormone modulators in pre-menopausal, healthy females. Circulating SHBG concentrations (nmol/L) will be assessed via serum pre- and post-Vitamin D intervention.

    Time frame: 3 weeks

Secondary outcomes

  1. Effects of Body Composition on Hormonal Changes Due to Vitamin D Supplementation in Young, Healthy Women

    Secondary analyses will evaluate the effect of body composition on change in testosterone concentration due to acute Vitamin D supplementation of pre-menopausal, healthy females. Testosterone (TT and FT) concentrations will be correlated with body composition metrics, i.e. fat and fat-free mass (kg), pre- and post-Vitamin D intervention.

    Time frame: 3 weeks

  2. Effects of Body Composition on Hormonal Changes Due to Vitamin D Supplementation in Young, Healthy Women

    Secondary analyses will evaluate the effect of body composition on change in testosterone concentration due to acute Vitamin D supplementation of pre-menopausal, healthy females. Testosterone (TT and FT) concentrations will be correlated with body composition metrics, i.e. BMI (kg/m\^2) as measured from height (m) and weight (kg), pre- and post-Vitamin D intervention.

    Time frame: 3 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Pilz S, Frisch S, Koertke H, Kuhn J, Dreier J, Obermayer-Pietsch B, Wehr E, Zittermann A. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2011 Mar;43(3):223-5. doi: 10.1055/s-0030-1269854. Epub 2010 Dec 10. PubMed 21154195 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Mar 2026 → Mar 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 24, 2024
StartActual
Jul 1, 2025
Primary completionEst.
Mar 5, 2027was Mar 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Enrolling by invitation
changed Nov 16, 2026
Primary completion
Mar 5, 2026→Mar 5, 2027
Nov 16, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Enrolling by invitation
    Primary completion Mar 5, 2026→Mar 5, 2027
    Study completion Sep 30, 2026→Sep 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06610968
Responsible party
Todd Schroeder (Professor, University of Southern California) — Principal investigator
First posted
Sep 24, 2024
Start date
Jul 1, 2025
Primary completion
Mar 5, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Giuliet L Kibler
principal investigator · University of Southern California - Division of Biokinesiology and Physical Therapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion